Is there a place for placebo controlled trials of antiepileptic drugs?

Shorvon, S.D.; Espir, M.L.E.; Steiner, T.J.; Dellaportas, C.I.; Rose, F. Clifford
November 1985
British Medical Journal (Clinical Research Edition);11/9/1985, Vol. 291 Issue 6505, p1328
Academic Journal
Examines the possibility of a placebo controlled trials on antiepileptic drugs in Great Britain. Uncertainty on the role of anticonvulsant drugs on epileptics; Impact of epileptic seizures on the psychology and social behavior of epileptics; Natural history of epilepsy.


Related Articles

  • Does informed consent influence therapeutic outcome? A clinical trial of the hypnotic activity of placebo in patients admitted to hospital. Dahan, R.; Caulin, C.; Figea, L.; Kanis, J.A.; Caulin, F.; Segrestaa, J.M. // British Medical Journal (Clinical Research Edition);8/9/1986, Vol. 293 Issue 6543, p363 

    Examines the impact of written informed consent on the results of clinical trial. Effect of placebo administered to patients with or without consent; Disadvantages inherent in acquiring informed consent; Concerns on the alteration of the outcome of the clinical trial.

  • Clinical trials: the viewpoint of children with a chronic illness compared with healthy children. Cherrill, J.; Hudson, H.; Cocking, C.; Unsworth, V.; Franck, L.; Fakis, A.; McIntyre, J.; Choonara, I. // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Mar2010, Vol. 95 Issue 3, p17 

    The views of over 200 children (11-16 years old, who were either healthy or attending paediatric medical clinics with a chronic illness) on issues relating to paediatric clinical trials were determined by a questionnaire. Children with a chronic illness had a better understanding of the concept...

  • Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients With Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial. Loftus, Edward V.; Feagan, Brian G.; Colombel, Jean-Frédéric; Rubin, David T.; Wu, Eric Q.; Yu, Andrew P.; Pollack, Paul F.; Chao, Jingdong; Mulani, Parvez // American Journal of Gastroenterology;Dec2008, Vol. 103 Issue 12, p3132 

    OBJECTIVES: We evaluated the effects of adalimumab maintenance therapy on health-related quality of life (HRQOL) in patients with moderate to severe Crohn's disease. METHODS: In a Phase III, randomized, double-blind clinical trial (CHARM) of moderate to severe Crohn's disease patients, HRQOL...

  • Development of a placebo effect model combined with a dropout model for bipolar disorder. Sun, Wan; Laughren, Thomas; Zhu, Hao; Hochhaus, Guenther; Wang, Yaning // Journal of Pharmacokinetics & Pharmacodynamics;Jun2013, Vol. 40 Issue 3, p359 

    The aim of this study was to develop a placebo model for bipolar disorder to help optimize clinical trial designs for studies targeting manic episodes in bipolar disorder. A bipolar disease database was built based on individual longitudinal data collected from over 3,000 patients in 11 clinical...

  • Negative Clinical Results from a Randomised, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy of Two Doses of Immunologically Enhanced, Grass Subcutaneous Immunotherapy Despite Dose-Dependent Immunological Response. Kleine-Tebbe, Jörg; Walmar, Mikkel; Bitsch-Jensen, Klaus; Decot, Elke; Pfaar, Oliver; Rojas, Dolores; Rodriguez, Fernando // Clinical Drug Investigation;Aug2014, Vol. 34 Issue 8, p577 

    Objective: Specific immunotherapy is the only treatment for the underlying allergic disease in patients with respiratory allergies. The primary objective of this trial was to evaluate the efficacy and safety of two maintenance doses of immunologically enhanced, standardised quality (SQ+) grass...

  • Nocebo vs. Placebo: The Challenges of Trial Design in Analgesia Research. Vase, L; Amanzio, M; Price, DD // Clinical Pharmacology & Therapeutics;Feb2015, Vol. 97 Issue 2, p143 

    The placebo effect in randomized clinical trials appears to have increased thereby contributing to problems of demonstrating statistically reliable effects of treatments that directly target biological mechanisms. The shortcomings of randomized clinical trials are currently discussed along with...

  • Is there a value for probiotic supplements in gestational diabetes mellitus? A randomized clinical trial. Dolatkhah, Neda; Hajifaraji, Majid; Abbasalizadeh, Fatemeh; Aghamohammadzadeh, Naser; Mehrabi, Yadollah; Abbasi, Mehran Mesgari; Mesgari Abbasi, Mehran // Journal of Health, Population & Nutrition;11/25/2015, Vol. 33, p1 

    Background: Although several studies have found probiotics encouraging in prevention of gestational diabetes mellitus (GDM), the evidence for the use of probiotics in diagnosed GDM is largely limited. The aim of this study was to assess the effect of a probiotic supplement capsule...

  • Does MRI lesion activity regress in secondary progressive multiple sclerosis? Zhao, Y.; Petkau, A. J.; Traboulsee, A.; Riddehough, A.; Li, D. K. B. // Multiple Sclerosis (13524585);Apr2010, Vol. 16 Issue 4, p434 

    Background: The rate of new contrast-enhancing lesions (CELs) on monthly magnetic resonance imaging (MRI) scans has been shown to decrease over a 9-month period in placebo-treated patients with relapsing-remitting (RR) multiple sclerosis (RRMS). Objective: We examined this phenomenon in...

  • Increasing Options for the Treatment of Osteoporosis. Khosla, Sundeep // New England Journal of Medicine;8/20/2009, Vol. 361 Issue 8, p818 

    The article presents information on the increasing number of U.S. Food and Drug Administration (FDA)-approved drugs for osteoporosis prevention and treatment. It highlights a study that appeared in the "New England Journal of Medicine" which involved 7,868 postmenopausal women with osteoporosis...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics